Towards precision medicine in diabetes? A critical review of glucotypes

PLoS Biol. 2021 Mar 11;19(3):e3000890. doi: 10.1371/journal.pbio.3000890. eCollection 2021 Mar.

Abstract

In response to a study previously published in PLOS Biology, this Formal Comment thoroughly examines the concept of 'glucotypes' with regard to its generalisability, interpretability and relationship to more traditional measures used to describe data from continuous glucose monitoring.

Trial registration: ClinicalTrials.gov NCT02695810.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Blood Glucose
  • Blood Glucose Self-Monitoring*
  • Diabetes Mellitus*
  • Humans
  • Precision Medicine

Substances

  • Blood Glucose

Associated data

  • ClinicalTrials.gov/NCT02695810

Grants and funding

A.H. acknowledges support by Steno Diabetes Center Aarhus, which is partially funded by an unrestricted donation from the Novo Nordisk Foundation. The European Foundation for the Study of Diabetes (EFSD) supported A.H. with the Albert Renold Travel Fellowship to visit The Maastricht Study group in Maastricht, the Netherlands. The Maastricht Study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (Grant 31O.041), Stichting De Weijerhorst (Maastricht, The Netherlands), the Pearl String Initiative Diabetes (Amsterdam, The Netherlands), the Cardiovascular Center (CVC, Maastricht, The Netherlands), CARIM School for Cardiovascular Diseases (Maastricht, The Netherlands), CAPHRI School for Public Health and Primary Care (Maastricht, The Netherlands), NUTRIM School for Nutrition and Translational Research in Metabolism (Maastricht, The Netherlands), Stichting Annadal (Maastricht, The Netherlands), Health Foundation Limburg (Maastricht, The Netherlands) and by unrestricted grants from Janssen-Cilag B.V. (Tilburg, The Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, The Netherlands), Sanofi-Aventis Netherlands B.V. (Gouda, The Netherlands), and Medtronic (Tolochenaz, Switzerland). The PRE-D Trial (NCT02695810) is funded by an unrestricted grant from the Novo Nordisk Foundation as an investigator-initiated study (K.F.), with further support from AstraZeneca AB, Ascensia Diabetes Care, the Danish Innovation Foundation, and the University of Copenhagen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.